These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 24550325)

  • 1. In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012.
    Walkty A; Adam H; Baxter M; Denisuik A; Lagacé-Wiens P; Karlowsky JA; Hoban DJ; Zhanel GG
    Antimicrob Agents Chemother; 2014 May; 58(5):2554-63. PubMed ID: 24550325
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Castanheira M; Davis AP; Mendes RE; Serio AW; Krause KM; Flamm RK
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866862
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Walkty A; Karlowsky JA; Baxter MR; Adam HJ; Zhanel GG
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study.
    Karlowsky JA; Adam HJ; Baxter MR; Lagacé-Wiens PR; Walkty AJ; Hoban DJ; Zhanel GG
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5600-11. PubMed ID: 23979759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance.
    Galani I; Nafplioti K; Adamou P; Karaiskos I; Giamarellou H; Souli M;
    BMC Infect Dis; 2019 Feb; 19(1):167. PubMed ID: 30770727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plazomicin activity against polymyxin-resistant Enterobacteriaceae, including MCR-1-producing isolates.
    Denervaud-Tendon V; Poirel L; Connolly LE; Krause KM; Nordmann P
    J Antimicrob Chemother; 2017 Oct; 72(10):2787-2791. PubMed ID: 29091226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009.
    Karlowsky JA; Adam HJ; Decorby MR; Lagacé-Wiens PR; Hoban DJ; Zhanel GG
    Antimicrob Agents Chemother; 2011 Jun; 55(6):2837-46. PubMed ID: 21402844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms.
    Castanheira M; Deshpande LM; Woosley LN; Serio AW; Krause KM; Flamm RK
    J Antimicrob Chemother; 2018 Dec; 73(12):3346-3354. PubMed ID: 30219857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.
    Sader HS; Castanheira M; Flamm RK
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin.
    Zhanel GG; Lawson CD; Zelenitsky S; Findlay B; Schweizer F; Adam H; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Expert Rev Anti Infect Ther; 2012 Apr; 10(4):459-73. PubMed ID: 22512755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial.
    Vega S; Dowzicky MJ
    Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):50. PubMed ID: 28701170
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Fleischmann WA; Greenwood-Quaintance KE; Patel R
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.
    Rodríguez-Avial I; Pena I; Picazo JJ; Rodríguez-Avial C; Culebras E
    Int J Antimicrob Agents; 2015 Dec; 46(6):616-21. PubMed ID: 26391381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The tigecycline evaluation and surveillance trial; assessment of the activity of tigecycline and other selected antibiotics against gram-positive and gram-negative pathogens from France collected between 2004 and 2016.
    Decousser JW; Woerther PL; Soussy CJ; Fines-Guyon M; Dowzicky MJ
    Antimicrob Resist Infect Control; 2018; 7():68. PubMed ID: 29876099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of plazomicin against β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE).
    Zhang Y; Kashikar A; Bush K
    J Antimicrob Chemother; 2017 Oct; 72(10):2792-2795. PubMed ID: 29091224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of plazomicin in combination with other antibiotics against multidrug-resistant Enterobacteriaceae.
    Thwaites M; Hall D; Stoneburner A; Shinabarger D; Serio AW; Krause KM; Marra A; Pillar C
    Diagn Microbiol Infect Dis; 2018 Dec; 92(4):338-345. PubMed ID: 30097297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin.
    Pillar CM; Aranza MK; Shah D; Sahm DF
    J Antimicrob Chemother; 2008 Mar; 61(3):595-602. PubMed ID: 18218646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial.
    Zhang Z; Chen M; Yu Y; Pan S; Liu Y
    Antimicrob Resist Infect Control; 2018; 7():152. PubMed ID: 30564308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative evaluation of plazomicin MICs obtained using agar dilution versus broth microdilution methods and impact of inoculum size against ESBL-producing Escherichia coli, carbapenemase-producing Klebsiella pneumoniae and methicillin-resistant Staphylococcus aureus clinical isolates.
    Emiliov T; Rodríguez-Avial I; López-Diaz MDC; Culebras E
    Diagn Microbiol Infect Dis; 2019 Nov; 95(3):114867. PubMed ID: 31402069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial activity of plazomicin against Enterobacteriaceae-producing carbapenemases from 50 Brazilian medical centers.
    Martins AF; Bail L; Ito CAS; da Silva Nogueira K; Dalmolin TV; Martins AS; Rocha JLL; Serio AW; Tuon FF
    Diagn Microbiol Infect Dis; 2018 Mar; 90(3):228-232. PubMed ID: 29223516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.